Back to Search
Start Over
Endogenous Luminal Surface Adenosine Signaling Regulates Duodenal Bicarbonate Secretion in Rats
- Source :
- Journal of Pharmacology and Experimental Therapeutics. 335:607-613
- Publication Year :
- 2010
- Publisher :
- American Society for Pharmacology & Experimental Therapeutics (ASPET), 2010.
-
Abstract
- Luminal ATP increases duodenal bicarbonate secretion (DBS) via brush border P2Y receptors. Because ATP is sequentially dephosphorylated to adenosine (ADO) and the brush border highly expresses adenosine deaminase (ADA), we hypothesized that luminal [ADO] regulators and sensors, including P1 receptors, ADA, and nucleoside transporters (NTs) regulate DBS. We measured DBS with pH and CO(2) electrodes, perfusing ADO ± adenosine receptor agonists or antagonists or the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTR(inh)-172 on DBS. Furthermore, we examined the effect of inhibitors of ADA or NT on DBS. Perfusion of AMP or ADO (0.1 mM) uniformly increased DBS, whereas inosine had no effect. The A(1/2) receptor agonist 5'-(N-ethylcarboxamido)-adenosine (0.1 mM) increased DBS, whereas ADO-augmented DBS was inhibited by the potent A(2B) receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide (MRS1754) (10 μM). Other selective adenosine receptor agonists or antagonists had no effect. The A(2B) receptor was immunolocalized to the brush border membrane of duodenal villi, whereas the A(2A) receptor was immunolocalized primarily to the vascular endothelium. Furthermore, ADO-induced DBS was enhanced by 2'-deoxycoformycin (1 μM) and formycin B (0.1 mM), but not by S-(4-nitrobenzyl)-6-thioinosine (0.1 mM), and it was abolished by CFTR(inh)-172 pretreatment (1 mg/kg i.p). Moreover, ATP (0.1 mM)-induced DBS was partially reduced by (1R,2S,4S,5S)-4-2-iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester tetraammonium salt (MRS2500) or 8-[4-[4-(4-chlorophenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine (PSB603) and abolished by both, suggesting that ATP is sequentially degraded to ADO. Luminal ADO stimulates DBS via A(2B) receptors and CFTR. ATP release, ecto-phosphohydrolases, ADA, and concentrative NT may coordinately regulate luminal surface ADO concentration to modulate ADO-P1 receptor signaling in rat duodenum.
- Subjects :
- Male
Adenosine monophosphate
Agonist
medicine.medical_specialty
P2Y receptor
Adenosine
Adenosine A2 Receptor Agonists
Adenosine Deaminase
Duodenum
medicine.drug_class
Receptor, Adenosine A2B
Rats, Sprague-Dawley
chemistry.chemical_compound
Adenosine Triphosphate
Adenosine deaminase
Equilibrative Nucleoside Transport Proteins
Internal medicine
Purinergic P1 Receptor Agonists
medicine
Animals
Intestinal Mucosa
Receptor
Pharmacology
biology
Receptors, Purinergic P1
Membrane Proteins
Membrane Transport Proteins
Receptor antagonist
Adenosine receptor
Adenosine Monophosphate
Adenosine A2 Receptor Antagonists
Rats
Perfusion
Bicarbonates
Endocrinology
Purinergic P1 Receptor Antagonists
chemistry
biology.protein
Molecular Medicine
Purinergic P2Y Receptor Agonists
Gastrointestinal, Hepatic, Pulmonary, and Renal
Signal Transduction
medicine.drug
Subjects
Details
- ISSN :
- 15210103 and 00223565
- Volume :
- 335
- Database :
- OpenAIRE
- Journal :
- Journal of Pharmacology and Experimental Therapeutics
- Accession number :
- edsair.doi.dedup.....dda5504395c1ce405cf867e41d0ca613